Denoci 120mg Injection consists of the active ingredient Denosumab. It is a medication used to treat osteoporosis, characterized by weakened bones. It is also prescribed to prevent bone complications in patients with certain types of cancer, such as multiple myeloma and bone metastases. Denoci 120mg Injection works by inhibiting a protein called RANK ligand, which plays a role in the breakdown of bone tissue. Studies proved it can significantly increase bone density, reducing fracture risk in postmenopausal women with osteoporosis and patients with cancer-related bone loss. Close monitoring of renal function may be necessary for patients with moderate renal impairment.

Denoci 120mg Injection should not be used in individuals with known hypersensitivity or allergic reactions to its components. Adequate calcium and vitamin D supplementation is required to ensure during the treatment. It is not approved for use in children and adolescents. Its safety and effectiveness in pediatric populations have not been established, so its use is contraindicated in individuals under 18. This medication should be used cautiously in individuals with pre-existing hypoparathyroidism, characterized by low parathyroid hormone levels.

Denoci 120mg Injection is used in the treatment of the following condition:

• Osteoporosis
• Bone loss due to hormonal therapy in breast or prostate cancer
• Multiple myeloma (cancer affects plasma cells in the bone marrow)
• Bone metastases (cancer that spreads to bone)

Denoci 120mg Injection has therapeutic effects that include reducing fracture risk, increasing bone mineral density, and improving overall bone health. By inhibiting bone resorption through its action on RANK ligands, this medication helps to strengthen bones and decrease the likelihood of fractures in individuals with osteoporosis or those at high risk. It also increases bone mineral density, an important marker of bone strength. These therapeutic effects contribute to improved bone health and a reduced risk of fractures, ultimately enhancing the quality of life for patients.

Inform the doctor about all the medicines, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Denoci 120mg Injection and reduce effectiveness by causing undesirable side effects.

• Denoci 120mg Injection should be stored in the refrigerator at a temperature between 2°C to 8°C (36°F to 46°F).
• Do not freeze it.
• Keep in the original package.
• Keep away from light, moisture, and heat.
• Keep away from children and pets.
• Avoid taking double doses for missed doses.

Denoci 120mg Injection is given as an injection by healthcare professionals. The dosage and duration of treatment will be based on the individual's condition and response to the medication and should be determined by a healthcare provider.

Denoci 120mg Injection can cause side effects like all medications, although not everyone who takes it will experience them. 

Serious:

• Osteonecrosis of the jaw (severe necrosis or death of jaw cells)
• Atypical femoral fractures
• Hypocalcemia (low blood calcium levels)

Common: 

• Injection site reactions
• Back pain
• Musculoskeletal pain
• Infections
• Abdominal pain
• Headache
• Hypophosphatemia (low blood phosphate levels)

Attend all scheduled appointments and follow-up visits to monitor your response to treatment and address any concerns or side effects. Tell your doctor about your medical history, previous infection, liver disease, and kidney disease. Inform your healthcare provider about any allergies or hypersensitivity reactions you may have. Seek immediate medical attention if you experience severe allergic reactions or other serious side effects. Additionally, Denoci 120mg Injection may affect calcium levels, so monitoring calcium levels and ensuring adequate calcium and vitamin D intake is important. Pregnant and breastfeeding women should consult a doctor before taking this medication. Avoid taking any vaccines during treatment. Regular dental examinations and good oral hygiene practices are recommended to minimize the risk of jaw osteonecrosis.

1. Amgen Ltd, Electronic medicines compendium (EMC), [ Revised on 13th May 2023], [ Accessed on 31st May 2023],https://www.medicines.org.uk/emc/files/pil.568.pdf
2. Amgen Manufacturing Limited, US Food and Drug Administration, [ Revised on November 2010] [ Accessed on 31st May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s007lbl.pdf 
3. Amgen Manufacturing Limited, US Food and Drug Administration, [ Revised on November 2022] [ Accessed on 31st May 2023], https://www.fda.gov/media/163378/download